Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatological Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynaecological Cancers
Haematological Malignancies
Haematology
Head and Neck Cancer
Immunotherapy
Leukaemia
Lung Cancer
Lymphoma
Multiple Myeloma
Endocrine Cancers
Ovarian Cancer
Pancreatic Cancer
Paediatric Oncology
Policy
Prostate Cancer
Renal Cancer
Sarcoma
Supportive Cancer Care
Soft Tissue Tumours
Rare Disease Day
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 1, 2025

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchEXPERT INSIGHTS

The impact of Isa-VRd on newly-diagnosed multiple myeloma: implications for standard of care treatment

Topics Covered:
Multiple Myeloma
Open Nav

Transplant eligible NDMM: The impact of quadruplet Isa-VRd treatment

In this video, Prof. Weisel describes the impact of Isa-VRd on MRD negativity status and PFS in patients with transplant eligible NDMM
Prof. Katja Weisel
Duration: 10:48

What was the treatment landscape and typical outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma when the GMMG-HD7 trial was initiated?

Start Time: 0:07

Please could you describe the patient population and key treatment phases, and provide a brief overview of previous key data from the GMMG-HD7 trial?

Start Time: 1:18

What were the final post-induction PFS results of the GMMG-HD7 trial?

Start Time: 4:35

In the landmark analysis, what was the effect of MRD negative and continued MRD negative status on PFS?

Start Time: 7:24

What are the implications of these results for patients and HCPs?

Start Time: 9:05

Transplant ineligible NDMM: The impact of quadruplet Isa-VRd treatment

In this video, Prof. Mohty describes the impact of Isa-VRd on MRD negativity dynamics and quality of life in patients with transplant ineligible NDMM
Prof. Mohammed Mohty
Duration: 12:23

What was the rationale for conducting the IMROZ study?

Start Time: 0:07

Please could you describe the patient population and key treatment phases, and provide a brief overview of previous key data from the IMROZ trial?

Start Time: 1:42

Further to the primary results presented previously for the IMROZ trial, what were MRD negativity dynamics over time with Isa-VRd vs VRd?

Start Time: 4:58

In the IMROZ HRQoL analysis, what impact did Isa-VRd vs VRd have on disease burden?

Start Time: 7:42

What are the implications of these results for patients and HCPs?

Start Time: 11:25
touchONCOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchONCOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Transplant eligible NDMM: The impact of quadruplet Isa-VRd treatment

In this video, Prof. Weisel describes the impact of Isa-VRd on MRD negativity status and PFS in patients with transplant eligible NDMM
Prof. Katja Weisel
Duration: 10:48

What was the treatment landscape and typical outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma when the GMMG-HD7 trial was initiated?

Start Time: 0:07

Please could you describe the patient population and key treatment phases, and provide a brief overview of previous key data from the GMMG-HD7 trial?

Start Time: 1:18

What were the final post-induction PFS results of the GMMG-HD7 trial?

Start Time: 4:35

In the landmark analysis, what was the effect of MRD negative and continued MRD negative status on PFS?

Start Time: 7:24

What are the implications of these results for patients and HCPs?

Start Time: 9:05

Transplant ineligible NDMM: The impact of quadruplet Isa-VRd treatment

In this video, Prof. Mohty describes the impact of Isa-VRd on MRD negativity dynamics and quality of life in patients with transplant ineligible NDMM
Prof. Mohammed Mohty
Duration: 12:23

What was the rationale for conducting the IMROZ study?

Start Time: 0:07

Please could you describe the patient population and key treatment phases, and provide a brief overview of previous key data from the IMROZ trial?

Start Time: 1:42

Further to the primary results presented previously for the IMROZ trial, what were MRD negativity dynamics over time with Isa-VRd vs VRd?

Start Time: 4:58

In the IMROZ HRQoL analysis, what impact did Isa-VRd vs VRd have on disease burden?

Start Time: 7:42

What are the implications of these results for patients and HCPs?

Start Time: 11:25

Activity overview

Faculty & disclosures

Overview
Faculty & disclosures

Overview

In patients with newly diagnosed multiple myeloma (NDMM), first-line treatment with the triplet combination of bortezomib, lenalidomide, and dexamethasone (VRd) is recommended.1,2 Previously, the addition of the anti-CD38 monoclonal antibody, isatuximab to VRd has been demonstrated to improve disease outcomes in both transplant eligible and ineligible patients with NDMM.3,4 In this activity, watch leading experts discuss the latest data on MRD negativity dynamics and quality of life with Isa-VRd in transplant ineligible patients, and MRD status and final PFS with Isa-VRd in transplant eligible patients.

Learning objectives

After viewing this activity, participants should be better able to:

  • Outline the effect of Isa-VRd vs VRd on QoL in the IMROZ trial of patients with transplant ineligible NDMM
  • Describe the MRD negativity dynamics of patients with transplant ineligible NDMM in the IMROZ trial treated with Isa-VRd vs VRd
  • Highlight the MRD negativity results from patients with transplant eligible NDMM treated with Isa-VRd vs VRd in the GMMG-HD7 trial
  • Understand the final PFS results from part 1 of the GMMG-HD7 trial of Isa-RVd in patients with transplant eligible NDMM

References4

List View
Grid View
1

Dimopoulos MA, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021r;32(3):309–322.

2

NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 2.2025 – April 11, 2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed June 2025).

3

Facon T, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(17):1597–1609.

4

Goldschmidt H, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810–e821.

Faculty & disclosures2

Prof. Mohammed Mohty

Saint-Antoine Hospital and Sorbonne University in Paris, France
More Information
Close Popup

Prof. Mohammed Mohty

Saint-Antoine Hospital and Sorbonne University in Paris, France
France

Biography

Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France, and is head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris. He is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and past chairman of the Acute Leukemia Working Party of the EBMT. In addition to publishing more than 1000 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, he also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International.

Disclosures

Consultancy, honoraria and advisory fees from: Adaptive Biotechnologies, Amgen, Astellas Pharma Inc., Bristol Myers Squibb, GSK, Janssen-Cilag EMEA, Jazz Pharmaceuticals, Medac Pharma, Novartis, OncoPep, Pfizer, Sanofi, Springer,  Stemline Therapeutics, Takeda Oncology and Therakos.

Prof. Katja Weisel

University Medical Center Hamburg-Eppendorf and University Cancer Center Hamburg, Germany
More Information
Close Popup

Prof. Katja Weisel

University Medical Center Hamburg-Eppendorf and University Cancer Center Hamburg, Germany
Germany

Biography

Katja Weisel is the deputy director and associate professor at University Medical Center Hamburg-Eppendorf (Oncology, Hematology and BMT) and Co-Director of the University Cancer Center Hamburg, Germany.  Her myeloma research interests focus on treatment optimization for high-risk myeloma, renally impaired myeloma patients, refractory myeloma patients, and radiographic methods to monitor myeloma disease. She is a member of the steering committee of the German-Speaking Multiple Myeloma Group (GMMG) where she is lead investigator of three GMMG trials, and has participated in more than 100 publications on multiple myeloma.

Disclosures

Advisory Role or Expert Testimony: Abbvie, Adaptive, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Cellcentric, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline and Takeda.  Honoraria: Abbvie, Adaptive, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline and Takeda.  Financing of Scientific Research: Amgen, Bristol Myers Squibb/Celgene, Janssen, Sanofi, GSK and Abbvie.

Video Navigation

Transplant eligible NDMM: The impact of quadruplet Isa-VRd treatment

In this video, Prof. Weisel describes the impact of Isa-VRd on MRD negativity status and PFS in patients with transplant eligible NDMM
Prof. Katja Weisel
Duration: 10:48

What was the treatment landscape and typical outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma when the GMMG-HD7 trial was initiated?

Start Time: 0:07

Please could you describe the patient population and key treatment phases, and provide a brief overview of previous key data from the GMMG-HD7 trial?

Start Time: 1:18

What were the final post-induction PFS results of the GMMG-HD7 trial?

Start Time: 4:35

In the landmark analysis, what was the effect of MRD negative and continued MRD negative status on PFS?

Start Time: 7:24

What are the implications of these results for patients and HCPs?

Start Time: 9:05

Transplant ineligible NDMM: The impact of quadruplet Isa-VRd treatment

In this video, Prof. Mohty describes the impact of Isa-VRd on MRD negativity dynamics and quality of life in patients with transplant ineligible NDMM
Prof. Mohammed Mohty
Duration: 12:23

What was the rationale for conducting the IMROZ study?

Start Time: 0:07

Please could you describe the patient population and key treatment phases, and provide a brief overview of previous key data from the IMROZ trial?

Start Time: 1:42

Further to the primary results presented previously for the IMROZ trial, what were MRD negativity dynamics over time with Isa-VRd vs VRd?

Start Time: 4:58

In the IMROZ HRQoL analysis, what impact did Isa-VRd vs VRd have on disease burden?

Start Time: 7:42

What are the implications of these results for patients and HCPs?

Start Time: 11:25

Add a Note

Note Time: 00:00
Save Note
touchONCOLOGY
touchEXPERT INSIGHTS

This content is intended for healthcare professionals

Please confirm you are a healthcare professional

Continue
Decline

This activity is funded by Sanofi. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Close Popup

This activity is funded by Sanofi.

This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by TMC to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.

The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.

Date of preparation: June 2025

Latest articles videos and clinical updates - straight to your inbox

Close Popup